Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Prostate Adenocarcinoma × bicalutamide × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Hirsutism 2 Thrombocytosis 1 Prostate Adenocarcinoma 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lower Urinary Tract Symptoms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Breast Neoplasms 1 Blast Crisis 1 Anemia 1

Interventions

enzalutamide 2 gallium 68 PSMA-11 1 entinostat 1 bicalutamide 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡